A Randomized Double-blind, Placebo-controlled Japanese Phase III Trial of ARQ 197 in Hepatocellular Carcinoma (HCC) (JET-HCC)

Kyowa Kirin

Status and phase: Completed; Phase 3

Conditions: Liver Cancer

Treatments: Drug: Placebo; Drug: ARQ197

Study type: Interventional

Funder types: Industry

Identifiers

NCT02029157

ARQ 197-009

Details and patient eligibility

About

The present clinical trial is aiming to evaluate efficacy of ARQ 197 in patients with hepatocellular carcinoma (HCC), who were resistant or intolerable to one systemic chemotherapy regimen including sorafenib.

Enrollment: 386 patients

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Informed consent form
• ≥20 years old
• Inoperable HCC which is not eligible for locoregional therapy
• Diagnosed as c-Met high in tumor sample
• Radiographic progression is confirmed during or after systemic chemotherapy including sorafenib, or those who are intolerance to the chemotherapy.
• Eastern Cooperative Oncology Group Performance Status (ECOG PS) is 0 or 1
• Child-Pugh Class A
• Having measurable target lesions which are defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1,
• Negative pregnancy test results
• Adequate organ function
• Life expectancy of at least 12 weeks

Exclusion criteria

• More than 2 prior systemic chemotherapy.
• Prior therapy of c-Met inhibitor (including antibody)
• Any systemic therapy within ≤2 weeks prior to the randomization
• Locoregional therapy within ≤4 weeks prior to randomization.
• Major surgery within ≤4 weeks prior to the randomization
• Concurrent cancer within ≤5 years prior to the randomization
• History of cardiac diseases
• Active clinically serious infections defined as ≥ Grade 3 according to Common Toxicity Criteria for Adverse Effects (CTCAE) 4.0
• Any psychological disorder affecting Informed Consent
• Diagnosis positive for anti-HIV antibody and/or anti-HTLV-1 antibody
• Blood or albumin transfusion within ≤14 days prior to the screening test
• Concurrent interferon therapy against Hepatitis B Virus (HBV)/ Hepatitis C Virus (HCV)
• Symptomatic brain metastases
• History of liver transplantation
• Inability to swallow oral medications
• Confirmed interstitial lung disease
• Pleural effusion and/or clinically significant ascites
• Pregnancy or breast-feeding
• Without consent to effective single or combined contraceptive methods

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

386 participants in 2 patient groups, including a placebo group

ARQ 197

Experimental group

Description:

Daily oral dose

Treatment:

Drug: ARQ197

Placebo

Placebo Comparator group

Description:

Daily oral dose

Treatment:

Drug: Placebo